<?xml version='1.0' encoding='utf-8'?>
<document id="16086645"><sentence text="Lopinavir/ritonavir in the treatment of human immunodeficiency virus infection."><entity charOffset="0-9" id="DDI-PubMed.16086645.s1.e0" text="Lopinavir" /><entity charOffset="10-19" id="DDI-PubMed.16086645.s1.e1" text="ritonavir" /><pair ddi="false" e1="DDI-PubMed.16086645.s1.e0" e2="DDI-PubMed.16086645.s1.e0" /><pair ddi="false" e1="DDI-PubMed.16086645.s1.e0" e2="DDI-PubMed.16086645.s1.e1" /></sentence><sentence text="The importance of combination antiretroviral therapy in HIV-infection has been well established" /><sentence text=" However, many available agents suffer shortcomings that limit their clinical value, including adverse effects, difficult dosing requirements and rapid development of resistance" /><sentence text=" Lopinavir/ritonavir (Kaletra) is a member of the protease inhibitor class, specifically designed to address some of these deficits"><entity charOffset="1-10" id="DDI-PubMed.16086645.s4.e0" text="Lopinavir" /><entity charOffset="11-20" id="DDI-PubMed.16086645.s4.e1" text="ritonavir" /><entity charOffset="22-29" id="DDI-PubMed.16086645.s4.e2" text="Kaletra" /><pair ddi="false" e1="DDI-PubMed.16086645.s4.e0" e2="DDI-PubMed.16086645.s4.e0" /><pair ddi="false" e1="DDI-PubMed.16086645.s4.e0" e2="DDI-PubMed.16086645.s4.e1" /><pair ddi="false" e1="DDI-PubMed.16086645.s4.e0" e2="DDI-PubMed.16086645.s4.e2" /><pair ddi="false" e1="DDI-PubMed.16086645.s4.e1" e2="DDI-PubMed.16086645.s4.e1" /><pair ddi="false" e1="DDI-PubMed.16086645.s4.e1" e2="DDI-PubMed.16086645.s4.e2" /></sentence><sentence text=" The drug is a coformulation of lopinavir with low-dose ritonavir, exploiting a favourable drug-drug interaction between the two that yields sustained increases in plasma levels of lopinavir"><entity charOffset="32-41" id="DDI-PubMed.16086645.s5.e0" text="lopinavir" /><entity charOffset="56-65" id="DDI-PubMed.16086645.s5.e1" text="ritonavir" /><entity charOffset="181-190" id="DDI-PubMed.16086645.s5.e2" text="lopinavir" /><pair ddi="false" e1="DDI-PubMed.16086645.s5.e0" e2="DDI-PubMed.16086645.s5.e0" /><pair ddi="false" e1="DDI-PubMed.16086645.s5.e0" e2="DDI-PubMed.16086645.s5.e1" /><pair ddi="false" e1="DDI-PubMed.16086645.s5.e0" e2="DDI-PubMed.16086645.s5.e2" /><pair ddi="false" e1="DDI-PubMed.16086645.s5.e1" e2="DDI-PubMed.16086645.s5.e1" /><pair ddi="false" e1="DDI-PubMed.16086645.s5.e1" e2="DDI-PubMed.16086645.s5.e2" /></sentence><sentence text=" In large-scale clinical trials, lopinavir/ritonavir has demonstrated superior therapeutic efficacy when compared with other protease inhibitors"><entity charOffset="33-42" id="DDI-PubMed.16086645.s6.e0" text="lopinavir" /><entity charOffset="43-52" id="DDI-PubMed.16086645.s6.e1" text="ritonavir" /><pair ddi="false" e1="DDI-PubMed.16086645.s6.e0" e2="DDI-PubMed.16086645.s6.e0" /><pair ddi="false" e1="DDI-PubMed.16086645.s6.e0" e2="DDI-PubMed.16086645.s6.e1" /></sentence><sentence text=" It exerts potent antiviral activity in both treatment-naive and experienced patients with an acceptable incidence of adverse effects" /><sentence text=" De novo development of resistance has not been described in large clinical trials with patients naive to antiretroviral therapy" /><sentence text=" Lopinavir/ritonavir has recently been approved for once-daily dosing in antiretroviral-naive patients"><entity charOffset="1-10" id="DDI-PubMed.16086645.s9.e0" text="Lopinavir" /><entity charOffset="11-20" id="DDI-PubMed.16086645.s9.e1" text="ritonavir" /><pair ddi="false" e1="DDI-PubMed.16086645.s9.e0" e2="DDI-PubMed.16086645.s9.e0" /><pair ddi="false" e1="DDI-PubMed.16086645.s9.e0" e2="DDI-PubMed.16086645.s9.e1" /></sentence><sentence text="" /></document>